IPSEN (OTCMKTS:IPSEY) Sees Large Decrease in Short Interest

Key Points

• Short interest in IPSEN has significantly decreased, dropping by 90.5% from 2,100 shares to just 200 shares as of July 15th.
• IPSEN's recent dividend payment increased to $0.2896 per share from a previous rate of $0.23, yielding 0.97% for shareholders.
• Deutsche Bank has maintained a "buy" rating on IPSEN shares, suggesting confidence in the company's performance.

IPSEN (OTCMKTS:IPSEY - Get Free Report) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 200 shares, adeclineof90.5% from the June 30th total of 2,100 shares. Based on an average daily volume of 1,000 shares, the days-to-cover ratio is currently 0.2 days. Currently,0.0% of the shares of the stock are short sold. Currently,0.0% of the shares of the stock are short sold. Based on an average daily volume of 1,000 shares, the days-to-cover ratio is currently 0.2 days.

IPSEN Price Performance

Shares of IPSEY remained flat at $32.22 during trading hours on Friday. The stock had a trading volume of 153 shares, compared to its average volume of 448. IPSEN has a one year low of $25.11 and a one year high of $33.00. The firm has a fifty day moving average of $30.35 and a 200 day moving average of $29.64.

IPSEN Increases Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were issued a dividend of $0.2896 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a dividend yield of 97.0%. This is a positive change from IPSEN's previous dividend of $0.23.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.